Literature DB >> 30100209

Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: A letter to the editor.

R B Katz1, M Toprak2, S T Wilkinson2, G Sanacora2, R Ostroff2.   

Abstract

Entities:  

Keywords:  Depression; Ketamine; Monoamine oxidase inhibitor; Safety; Treatment-refractory

Mesh：

Substances：

Year:  2018        PMID： 30100209      PMCID： PMC6292194          DOI： 10.1016/j.genhosppsych.2018.05.007

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN： 0163-8343            Impact factor:   3.238


× No keyword cloud information.
  12 in total

Review 1.  Adverse drug interactions in anesthesia.

Authors:  J G Bovill
Journal:  J Clin Anesth       Date:  1997-09       Impact factor: 9.452

2.  Antidepressive treatment with monoamine oxidase inhibitors and the occurrence of intraoperative hemodynamic events: a retrospective observational cohort study.

Authors:  Ingrid M M van Haelst; Wilton A van Klei; Hieronymus J Doodeman; Cor J Kalkman; Toine C G Egberts
Journal:  J Clin Psychiatry       Date:  2012-07-10       Impact factor: 4.384

3.  Antidepressants do not increase the lethality of ketamine in mice.

Authors:  D L Bruce; L Capan
Journal:  Br J Anaesth       Date:  1983-05       Impact factor: 9.166

4.  Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions.

Authors:  Patricio Riva-Posse; Collin M Reiff; Johnathan A Edwards; Gregory P Job; Gail C Galendez; Steven J Garlow; Tammy C Saah; Boadie W Dunlop; William M McDonald
Journal:  J Affect Disord       Date:  2018-02-21       Impact factor: 4.839

5.  Ketamine decreases intracranial pressure and electroencephalographic activity in traumatic brain injury patients during propofol sedation.

Authors:  J Albanèse; S Arnaud; M Rey; L Thomachot; B Alliez; C Martin
Journal:  Anesthesiology       Date:  1997-12       Impact factor: 7.892

6.  Ketamine induction and monoamine oxidase inhibitors.

Authors:  D J Doyle
Journal:  J Clin Anesth       Date:  1990 Sep-Oct       Impact factor: 9.452

Review 7.  KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.

Authors:  Chadi G Abdallah; Thomas G Adams; Benjamin Kelmendi; Irina Esterlis; Gerard Sanacora; John H Krystal
Journal:  Depress Anxiety       Date:  2016-04-06       Impact factor: 6.505

8.  Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: A report of two cases.

Authors:  Lucie Bartova; Sonja E Vogl; Mara Stamenkovic; Nicole Praschak-Rieder; Angela Naderi-Heiden; Siegfried Kasper; Matthaeus Willeit
Journal:  Eur Neuropsychopharmacol       Date:  2015-08-06       Impact factor: 4.600

Review 9.  A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.

Authors:  Gerard Sanacora; Mark A Frye; William McDonald; Sanjay J Mathew; Mason S Turner; Alan F Schatzberg; Paul Summergrad; Charles B Nemeroff
Journal:  JAMA Psychiatry       Date:  2017-04-01       Impact factor: 21.596

10.  A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders.

Authors:  Samuel T Wilkinson; Mesut Toprak; Mason S Turner; Steven P Levine; Rachel B Katz; Gerard Sanacora
Journal:  Am J Psychiatry       Date:  2017-07-01       Impact factor: 18.112
View more
  4 in total

1.  Next-Step Treatment Considerations for Patients With Treatment-Resistant Depression That Responds to Low-Dose Intravenous Ketamine.

Authors:  William V Bobo; Patricio Riva-Posse; Fernando S Goes; Sagar V Parikh
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-04-23

2.  Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively.

Authors:  Samuel R Chamberlain; David S Baldwin
Journal:  CNS Drugs       Date:  2021-07-09       Impact factor: 5.749

3.  Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial.

Authors:  Sanne Y Smith-Apeldoorn; Jolien K E Veraart; Jeanine Kamphuis; Antoinette D I van Asselt; Daan J Touw; Marije Aan Het Rot; Robert A Schoevers
Journal:  BMC Psychiatry       Date:  2019-11-29       Impact factor: 3.630

4.  Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study.

Authors:  Vera M Ludwig; Cathrin Sauer; Allan H Young; James Rucker; Michael Bauer; Hannelore Findeis; Philipp Ritter
Journal:  CNS Drugs       Date:  2021-07-20       Impact factor: 5.749
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.